Scientists at the University of Birmingham have developed a type of eye drop which could potentially revolutionise the treatment of one of the leading causes of blindness in the UK.
The results of the collaborative research, published today in Investigative Opthamology and Visual Science, could spell the end of painful injections directly into the eye to treat the increasingly common eye disorder known as age-related macular degeneration (AMD).
AMD affects more than 600,000 people in the UK and predictions suggest this figure could rise sharply in future because of an ageing population.
A painless condition which causes people to gradually lose their central vision, usually in both eyes, AMD is currently treated by repeated injections into the eye on a monthly basis over at least three years.
This is a problem because, apart from being an unpleasant procedure for patients to undergo, the injections can cause tearing and infections inside the eye and an increased risk of blindness.
Now scientists led by biochemist Dr Felicity de Cogan, from the University of Birmingham’s Institute of Inflammation and Ageing, have invented a method of delivering the injected drug as an eye drop instead, and their laboratory research has obtained the same outcomes as the injected drug.
The drop uses a cell-penetrating peptide (CPP) to deliver the drug to the relevant part of the eye within minutes.
Dr de Cogan said: “The CPP-drug has the potential to have a significant impact on the treatment of AMD by revolutionising drug-delivery options.
“Efficacious self-administered drug application by eye drop would lead to a significant reduction in adverse outcomes and health care costs compared with current treatments.
“The CPP-plus drug complex also has potential application to other chronic ocular diseases that require drug delivery to the posterior chamber of the eye.
“We believe this is going to be very important in terms of empowering of patients and reducing the cost of treatment to the NHS.”
The Latest on: Age-related macular degeneration
- (2018-2023) Global Age-related Macular Degeneration Industry-Report Analysis Added by MarketResearchNest.com on February 19, 2018 at 2:51 am
Global Age-related Macular Degeneration Market Report 2017 offered by MarketResearchNest contains a market overview of the industry which talks about market size, product scope, market revenue, growth opportunities, sales volumes and figures, growth ... […]
- Cortina Asset Management Upped By $8.21 Million Its Silicon Laboratories (SLAB) Position; Regeneron Pharmaceuticals (REGN) Sentiment Is 1.17 on February 18, 2018 at 8:56 am
The company has market cap of $35.71 billion. The Company’s products include EYLEA injection for the treatment of neovascular age-related macular degeneration, diabetic macular edema, and macular edema following retinal vein occlusion; Praluent injection ... […]
- Healthy Living And Macular Degeneration: Tips To Protect Your Vision on February 15, 2018 at 2:13 am
(NAPSI)—Here’s health news you may be glad to see: A healthy lifestyle may reduce your risk of getting vision diseases such as age-related macular degeneration (AMD), which can damage central vision and currently affects 11 million Americans. […]
- Phase II Data Support Potential for Novel Anti-VEGF/Anti-Angiopoietin-2 Bispecific Antibody, RG7716, for People With Diabetic Macular Edema on February 12, 2018 at 1:33 am
Lucentis is FDA-approved for the treatment of patients with wet age-related macular degeneration (AMD), macular edema after retinal vein occlusion (RVO), diabetic macular edema (DME), diabetic retinopathy (DR) and myopic choroidal neovascularization (mCNV). […]
- Age-Related Macular Degeneration: Leading Cause of Blindness in Seniors on February 10, 2018 at 11:30 am
The Hawaiian Eye Center announces that Age-Related Macular Degeneration (AMD) affects more than 2 million Americans and is the leading cause of severe vision loss for those 50 years and older. It is a progressive and usually painless eye disease that ... […]
via Google News and Bing News